Advertisement

Antiviral Therapy and Local Treatment for Herpes Zoster

  • Anne A. Gershon
Chapter

Abstract

In the twenty-first century, there is great interest in prevention of zoster, both in healthy and immunocompromised patients. Successful prevention of clinical reactivation of varicella zoster virus (VZV) is obviously preferable to treatment after VZV has reactivated and caused disease. Despite the development of effective zoster vaccines [1, 2], however, there will continue to be a need for antiviral therapy for zoster in patients who have not received immunization or in whom a vaccine has not been entirely effective. Today, most individuals who develop zoster, particularly if they are immunocompromised or over 50 years old, are recommended to receive specific therapy mainly to decrease morbidity from VZV infection; death from zoster is uncommon or rare [3]. Therapy of zoster, even if given early after onset, unfortunately, probably does not prevent development of postherpetic neuralgia (PHN), as discussed below. On the other hand, relief of pain and promotion of healing of the rash of zoster are obviously greatly welcomed by patients, and antiviral therapy is given to most zoster patients.

Notes

Acknowledgments

Grant support: R01DK093094; Biken Institute of Osaka University.

References

  1. 1.
    Oxman MN, Levin MJ, Johnson GR et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284CrossRefGoogle Scholar
  2. 2.
    Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096 .2137-21CrossRefGoogle Scholar
  3. 3.
    Mahamud A et al (2012) Herpes Zoster-Related Deaths in the United States: Validity of Death Certificates and Mortality Rates 1979–2007. Clin Infect Dis 55:960–966CrossRefPubMedGoogle Scholar
  4. 4.
    Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73:7–13CrossRefPubMedGoogle Scholar
  5. 5.
    YIn M, Brust J, Tieu H, Hammer S (2009) Antiherpesvirus, anti-hepatitis virus, and anti-respiratory virus agents. In: Richman D, Whitley R, Hayden F (eds) Clinical virology, 3rd edn. ASM Press, Washington, DC, pp. 217–264Google Scholar
  6. 6.
    Tilson HH (1988) Monitoring the safety of antivirals. The example of the acyclovir experience. Am J Med 85:116–122PubMedGoogle Scholar
  7. 7.
    Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ (1995) Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39:1546–1553CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kost RG, Straus SE (1996) Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med 335:32–42CrossRefPubMedGoogle Scholar
  9. 9.
    Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ (1996) Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta analysis of placebo controlled trials. Clin Infect Dis 22:341–347CrossRefPubMedGoogle Scholar
  10. 10.
    Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ (2000) Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 9:863–869CrossRefPubMedGoogle Scholar
  11. 11.
    Alper BS, Lewis PR (2000) Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 49:255–264PubMedGoogle Scholar
  12. 12.
    Whitley RJ, Weiss H, Gnann JW Jr et al (1996) Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 125:376–383CrossRefGoogle Scholar
  13. 13.
    Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman R (2001) A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 19:13–22CrossRefPubMedGoogle Scholar
  14. 14.
    Chen N, Li Q, Yang J, Zhou M, Zhou D He L (2014) Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev (2):CD006866Google Scholar
  15. 15.
    Dworkin RH, Johnson RW, Breuer J et al (2007) Recommendations for the management of herpes zoster. Clin Infect Dis 44(Suppl 1):S1–S26CrossRefGoogle Scholar
  16. 16.
    Nagel MA, Gilden D (2016) Developments in varicella zoster virus vasculopathy. Curr Neurol Neurosci Rep 16:12CrossRefGoogle Scholar
  17. 17.
    Gilden D, White T, Boyer PJ et al (2016) Varicella zoster virus infection in granulomatous arteritis of the aorta. J Infect Dis 213(12):1866–1871CrossRefGoogle Scholar
  18. 18.
    Gilden D, Nagel MA (2016) Varicella zoster virus and giant cell arteritis. Curr Opin Infect Dis 29(3):275–279CrossRefGoogle Scholar
  19. 19.
    Mehta SK, Tyring SK, Gilden DH et al (2008) Varicella-zoster virus in the saliva of patients with herpes zoster. J Infect Dis 197:654–657CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL (2004) Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 72:174–179CrossRefPubMedGoogle Scholar
  21. 21.
    Cohrs RJ, Mehta SK, Schmid DS, Gilden DH, Pierson DL (2008) Asymptomatic reactivation and shed of infectious VZV in astronauts. J Med Virol 80:1116–1122CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Birlea M, Cohrs RJ, Bos N, Mehta SK, Pierson DL, Gilden D (2014) Search for VZV DNA in saliva of healthy individuals aged 20-59 years. J Med Virol 86:360–362CrossRefPubMedGoogle Scholar
  23. 23.
    Papaevangelou V, Quinlivan M, Lockwood J et al (2013) Subclinical VZV reactivation in immunocompetent children hospitalized in the ICU associated with prolonged fever duration. Clin Microbiol Infect 5:E245–E251CrossRefGoogle Scholar
  24. 24.
    Gershon AA, Chen J, Gershon MD (2015) Use of saliva to identify varicella-zoster virus (VZV) infection of the gut. Clin Infect Dis 61:536–544CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gilden D, White TM, Nagae L, Gurdin WH, Boyer PJ, Nagel MA (2015) Successful antiviral treatment of giant cell arteritis and takayasu arteritis. JAMA Neurol 72:943–946CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cheng-Ching E, Jones S, Hui FK et al (2015) High-resolution MRI vessel wall imaging in varicella zoster virus vasculopathy. J Neurol Sci 351:168–173CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Edelman DA, Antaki F, Basson MD, Salwen WA, Gruber SA, Losanoff JE (2009) Ogilvie syndrome and herpes zoster: case report and review of the literature. J Emerg Med 39:696–700CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Columbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations